BiondVax Pharmaceuticals Ltd. (TASE:BNDX) today reported success in the Phase II clinical trial of its Multimeric-001 universal flu vaccine. The vaccine was found to be safe, with no side significant effects compared with the control group, and it activated the body's two immune systems.
The trial at Hadassah Medical Organization in Jerusalem and Sourasky Medical Center (Ichilov Hospital) in Tel Aviv included 120 patients over the age of 65. The trial examined the vaccine's safety and immunological response.
This was BiondVax's fourth clinical trial of its universal flu vaccine on two groups of adult populations. The previous trials on populations aged 18-49 and 55-75 were all successful.
BiondVax has also requested Yorkville Advisors LLC for a $500,000 investment, in exchange for an allotment of 2,022,354, under the standby equity purchase agreement (SEPA) with Yorkville unit YA Global Investments LP.
BiondVax's share price rose 3.5% by midday, after an initial jump of 11% following the announcement, to NIS 1.44, giving a market cap of NIS 57 million.
Published by Globes [online], Israel business news - www.globes-online.com - on February 16, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012